Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$2.48 USD
+0.30 (13.76%)
Updated Apr 30, 2024 03:59 PM ET
2-Buy of 5 2
B Value B Growth F Momentum B VGM
Income Statements
Fiscal Year end for Cresco Labs Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 771 | 843 | 822 | 476 | 129 |
Cost Of Goods | 409 | 436 | 415 | 192 | 64 |
Gross Profit | 362 | 407 | 406 | 284 | 64 |
Selling & Adminstrative & Depr. & Amort Expenses | 450 | 491 | 624 | 228 | 98 |
Income After Depreciation & Amortization | -88 | -84 | -217 | 56 | -34 |
Non-Operating Income | 2 | 15 | 12 | -9 | -9 |
Interest Expense | 61 | 58 | 51 | 39 | 8 |
Pretax Income | -147 | -127 | -257 | 7 | -51 |
Income Taxes | 33 | 89 | 40 | 44 | 14 |
Minority Interest | -4 | -4 | 23 | 45 | -22 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -180 | -216 | -297 | -37 | -65 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -176 | -212 | -320 | -82 | -43 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | -27 | -172 | 96 | -22 |
Depreciation & Amortization (Cash Flow) | 69 | 58 | 45 | 40 | 12 |
Income After Depreciation & Amortization | -88 | -84 | -217 | 56 | -34 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 323.82 | 298.16 | 262.33 | 210.47 | NA |
Diluted EPS Before Non-Recurring Items | -0.17 | -0.20 | -0.05 | -0.39 | NA |
Diluted Net EPS (GAAP) | -0.54 | -0.71 | -1.22 | -0.39 | NA |
Fiscal Year end for Cresco Labs Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 188.24 | 190.56 | 197.89 | 194.20 |
Cost Of Goods | NA | 92.09 | 96.92 | 111.19 | 108.32 |
Gross Profit | NA | 96.15 | 93.64 | 86.70 | 85.88 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 69.05 | 201.40 | 97.45 | 82.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 27.10 | -107.76 | -10.75 | 3.59 |
Non-Operating Income | NA | 0.05 | 0.33 | 0.40 | 0.96 |
Interest Expense | NA | 14.33 | 11.76 | 19.18 | 15.55 |
Pretax Income | NA | 12.82 | -119.19 | -29.53 | -11.00 |
Income Taxes | NA | 7.95 | -5.75 | 13.94 | 16.81 |
Minority Interest | NA | 2.23 | 2.13 | -6.93 | -1.76 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 4.87 | -113.45 | -43.46 | -27.81 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 2.63 | -115.57 | -36.53 | -26.05 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 323.82 | 337.47 | 313.62 | 304.09 |
Diluted EPS Before Non-Recurring Items | NA | 0.01 | -0.04 | -0.05 | -0.09 |
Diluted Net EPS (GAAP) | NA | 0.01 | -0.34 | -0.12 | -0.09 |